Psoriasis Uncovered Ep. 80 "The Oral Agent Armamentarium for Psoriasis"
Jul 7, 2020
Dr. Kenneth Gordon, a leading dermatologist and expert in psoriasis treatment, shares insights on oral agents for managing psoriasis. He discusses the factors influencing patients' choices for oral medications, highlighting the efficacy of treatments like methotrexate and apremilast. The conversation delves into cyclosporine's rapid effectiveness and the promise of newer options like tofacitinib. Dr. Gordon also offers an optimistic view on future non-biologic therapies, including fumaric acid esters, which are gaining traction in Europe.
AI Snips
Chapters
Transcript
Episode notes
Oral Therapy Selection Factors
- Oral systemic therapies are chosen mainly for extensive or resistant psoriasis and when patients prefer non-injectable treatments.
- Cost and needle phobia influence choosing oral treatments over biologics.
Prioritize Patient Preference
- Patient preference strongly influences whether oral or injectable treatments are used.
- It's important to maintain a variety of treatment options to match patient comfort and concerns.
Methotrexate Efficacy and Role
- Methotrexate is effective in about half of psoriasis patients and remains a useful treatment despite newer options.
- It is primarily anti-inflammatory at low doses, distinct from its original chemotherapy use.